Emgality (galcanezumab-gnlm) is Eli Lilly's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Emgality is Eli Lilly and Company's galcanezumab-gnlm, a monoclonal antibody that blocks the CGRP receptor pathway and is administered by subcutaneous injection for the preventive treatment of migraine in adults. Its official product page presents dosing information and patient support materials.
AgoneX Biopharmaceuticals frames its histamine receptor modulation program against CGRP monoclonal antibodies such as Emgality, which together with the receptor antagonists constitute the marketed prophylactic class AGX-201 would compete against.
| Attribute | Emgality | AGX-201 | |
|---|---|---|---|
| Provider | |  | |
| Founded | 1876 | 2011 | |
| Sells To | Consumers, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software, Transactional | Recurring, Software | |
| Ownership | Public | Private |
Provider
Founded 1876
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider
Founded 2011
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Ajovy (fremanezumab-vfrm) is Teva's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Nurtec ODT is a Pfizer oral gepant for acute migraine treatment and episodic migraine prevention.
Vyepti (eptinezumab-jjmr) is Lundbeck's intravenous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Ajovy (fremanezumab-vfrm) is Teva's subcutaneous CGRP monoclonal antibody indicated for the preventive treatment of migraine in adults.
Nurtec ODT is a Pfizer oral gepant for acute migraine treatment and episodic migraine prevention.
Qulipta (atogepant) is AbbVie's once-daily oral CGRP receptor antagonist indicated for the preventive treatment of migraine in adults.
